1
|
Montemagno C, Hagege A, Borchiellini D, Thamphya B, Rastoin O, Ambrosetti D, Iovanna J, Rioux-Leclercq N, Porta C, Negrier S, Ferrero JM, Chamorey E, Pagès G, Dufies M. Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma. Oncoimmunology 2020; 9:1846901. [PMID: 33299657 PMCID: PMC7714499 DOI: 10.1080/2162402x.2020.1846901] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Metastatic clear cell renal cell carcinoma (mccRCC) benefits from several treatment options in the first-line setting with VEGFR inhibitors and/or immunotherapy including anti-PD-L1 or anti-PD1 agents. Identification of predictive biomarkers is highly needed to optimize patient care. Circulating markers could reflect the biology of metastatic disease. Therefore, we evaluated soluble forms of PD-L1 (sPD-L1) and PD-1 (sPD-1) in mccRCC patients. The levels of sPD-L1 and sPD-1 were evaluated from plasma samples of mccRCC patients before they received a first-line treatment (T0) by the VEGFR inhibitor sunitinib (50 patients) or by the anti-VEGF bevacizumab (37 patients). The levels of sPD-L1 and sPD-1 were correlated to clinical parameters and progression-free survival (PFS). High levels of sPD-1 or sPDL1 were not correlated to PFS under bevacizumab while they were independent prognostic factors of PFS in the sunitinib group. Patients with high T0 plasmatic levels of sPD-L1 had a shorter PFS (11.3 vs 22.5 months, p = .011) in the sunitinib group. Equivalent shorter PFS was found with high levels of sPD-1 (8.6 vs 14.1 months, p = .009). mccRCC patients with high plasmatic levels of sPD-L1 or sPD-1 are poor responders to sunitinib. sPD-L1 or sPD-1 could be a valuable tool to guide the optimal treatment strategy including VEGFR inhibitor.
Collapse
Affiliation(s)
- Christopher Montemagno
- Biomedical Department, Centre Scientifique De Monaco, principally of Monaco.,Centre Antoine Lacassagne, University Cote d'Azur (UCA), Institute for research on cancer and aging of Nice, CNRS UMR 7284; INSERM U1081, Centre Antoine Lacassagne, Nic, France.,LIA ROPSE, Laboratoire International Associé Université Côte d'Azur - Centre Scientifique de Monaco
| | - Anais Hagege
- Centre Antoine Lacassagne, University Cote d'Azur (UCA), Institute for research on cancer and aging of Nice, CNRS UMR 7284; INSERM U1081, Centre Antoine Lacassagne, Nic, France.,LIA ROPSE, Laboratoire International Associé Université Côte d'Azur - Centre Scientifique de Monaco
| | - Delphine Borchiellini
- University Côte d'Azur, Centre Antoine Lacassagne, Department of Medical Oncology, University Côte d'Azur, Nice, France
| | - Brice Thamphya
- Centre Antoine Lacassagne, Department of Statistic, University Côte d'Azur, Nice, France
| | - Olivia Rastoin
- Centre Antoine Lacassagne, University Cote d'Azur (UCA), Institute for research on cancer and aging of Nice, CNRS UMR 7284; INSERM U1081, Centre Antoine Lacassagne, Nic, France.,LIA ROPSE, Laboratoire International Associé Université Côte d'Azur - Centre Scientifique de Monaco
| | - Damien Ambrosetti
- Centre Hospitalier Universitaire (CHU) De Nice, Hôpital Pasteur, Central Laboratory of Pathology University Côte d'Azur, Nice, France
| | - Juan Iovanna
- Team Pancreatic Cancer, Centre De Recherche En Cancérologie De Marseille (CRCM), Marseille, France
| | | | - Camillio Porta
- Department of Biomedical Sciences and Human Oncology, I.R.C.C.S. San Matteo University Hospital, Pavia, Italy (Present Affiliation: University of Bari 'A. Moro', Bari, Italy
| | - Sylvie Negrier
- Centre Léon Bérard, University Hospital De Lyon, Lyon, France
| | - Jean-Marc Ferrero
- University Côte d'Azur, Centre Antoine Lacassagne, Department of Medical Oncology, University Côte d'Azur, Nice, France
| | - Emmanuel Chamorey
- Centre Antoine Lacassagne, Department of Statistic, University Côte d'Azur, Nice, France
| | - Gilles Pagès
- Biomedical Department, Centre Scientifique De Monaco, principally of Monaco.,Centre Antoine Lacassagne, University Cote d'Azur (UCA), Institute for research on cancer and aging of Nice, CNRS UMR 7284; INSERM U1081, Centre Antoine Lacassagne, Nic, France.,LIA ROPSE, Laboratoire International Associé Université Côte d'Azur - Centre Scientifique de Monaco
| | - Maeva Dufies
- Biomedical Department, Centre Scientifique De Monaco, principally of Monaco.,LIA ROPSE, Laboratoire International Associé Université Côte d'Azur - Centre Scientifique de Monaco
| |
Collapse
|